• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

改良的德格拉蒙方案联合奥沙利铂用于晚期结直肠癌的一线治疗。

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.

作者信息

Braun M S, Adab F, Bradley C, McAdam K, Thomas G, Wadd N J, Rea D, Philips R, Twelves C, Bozzino J, MacMillan C, Saunders M P, Counsell R, Anderson H, McDonald A, Stewart J, Robinson A, Davies S, Richards F J, Seymour M T

机构信息

Cancer Research UK Centre in Leeds, Cookridge Hospital, Leeds LS16 6QB, UK.

出版信息

Br J Cancer. 2003 Oct 6;89(7):1155-8. doi: 10.1038/sj.bjc.6601237.

DOI:10.1038/sj.bjc.6601237
PMID:14520437
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2394314/
Abstract

We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.

摘要

我们之前在一项针对转移性结直肠癌患者的单中心研究中报告了奥沙利铂和改良的德格拉蒙方案（OxMdG）的高活性。我们现在报告在14个中心治疗的另外56例患者的结果。观察到3级和4级毒性发生率较低，无毒性死亡。客观缓解率为CR/PR = 53%；NC = 34.7%；PD = 12.2%。中位进展时间为8.3个月，总生存期为14.5个月。该方案比基于传统德格拉蒙方案的方案更方便，但活性高且耐受性良好；它是当前英国医学研究理事会3期试验的一部分。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0abf/2394314/f9d6cb7b88b7/89-6601237f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0abf/2394314/0953944133f2/89-6601237f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0abf/2394314/f9d6cb7b88b7/89-6601237f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0abf/2394314/0953944133f2/89-6601237f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0abf/2394314/f9d6cb7b88b7/89-6601237f2.jpg

相似文献

1
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.改良的德格拉蒙方案联合奥沙利铂用于晚期结直肠癌的一线治疗。
Br J Cancer. 2003 Oct 6;89(7):1155-8. doi: 10.1038/sj.bjc.6601237.
2
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.一种用于晚期结直肠癌的氟尿嘧啶单药及联合奥沙利铂的“改良德格拉蒙”方案。
Br J Cancer. 2002 Aug 12;87(4):393-9. doi: 10.1038/sj.bjc.6600467.
3
The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.奥沙利铂联合持续输注±推注5-氟尿嘧啶和亚叶酸钙用于经基于5-氟尿嘧啶的化疗后进展的转移性结直肠癌的价值：一项GISCAD（意大利消化道研究组）癌症II期试验。
Tumori. 2000 Nov-Dec;86(6):465-9. doi: 10.1177/030089160008600606.
4
Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy.多中心II期研究：对接受过化疗的转移性结直肠癌患者每两个月进行一次奥沙利铂联合亚叶酸钙和5-氟尿嘧啶的分次给药治疗。
Oncol Rep. 2003 Jan-Feb;10(1):65-9.
5
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.MRC COIN试验中与奥沙利铂联合氟嘧啶（无论有无西妥昔单抗）相关的毒性反应经验。
Br J Cancer. 2009 Jan 27;100(2):251-8. doi: 10.1038/sj.bjc.6604877.
6
Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).梅奥方案联合三种不同的二线化疗方案序贯治疗晚期结直肠癌（ACRC）患者。
J Exp Clin Cancer Res. 2004 Sep;23(3):395-401.
7
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.多中心II期研究：每两个月使用高剂量亚叶酸、氟尿嘧啶输注和奥沙利铂治疗对相同亚叶酸和氟尿嘧啶方案耐药的转移性结直肠癌。
J Clin Oncol. 1999 Nov;17(11):3560-8. doi: 10.1200/JCO.1999.17.11.3560.
8
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.贝伐单抗联合5-氟尿嘧啶、亚叶酸钙和奥沙利铂与贝伐单抗联合卡培他滨和奥沙利铂治疗转移性结直肠癌：一项基于大型注册队列分析的结果
BMC Cancer. 2014 May 7;14:323. doi: 10.1186/1471-2407-14-323.
9
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer.一项四臂、随机、多中心的II期试验，评估奥沙利铂联合不同给药方案的5-氟尿嘧啶作为一线治疗方案用于既往未接受过治疗的晚期结直肠癌的疗效。
Clin Colorectal Cancer. 2008 Mar;7(2):134-9. doi: 10.3816/ccc.2008.n.018.
10
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. upfront FOLFOXIRI 联合贝伐珠单抗和进展后再引入与 mFOLFOX6 联合贝伐珠单抗后序贯 FOLFIRI 联合贝伐珠单抗治疗转移性结直肠癌患者（TRIBE2）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

引用本文的文献

1
Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial.利鲁唑联合mFOLFOX6和贝伐单抗治疗转移性结直肠癌患者：一项I期临床试验
Clin Cancer Res. 2025 Jun 3;31(11):2115-2123. doi: 10.1158/1078-0432.CCR-24-3964.
2
Inoperable metastatic colorectal cancer with primary tumour : Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre).伴有原发性肿瘤的不可切除转移性结直肠癌：评估原发性肿瘤和转移部位对一线全身治疗的不一致反应以及原发性肿瘤引起的并发症（来自爱尔兰癌症中心的经验）
Mol Clin Oncol. 2022 Feb;16(2):40. doi: 10.3892/mco.2021.2472. Epub 2021 Dec 21.
3

本文引用的文献

1
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.一种用于晚期结直肠癌的氟尿嘧啶单药及联合奥沙利铂的“改良德格拉蒙”方案。
Br J Cancer. 2002 Aug 12;87(4):393-9. doi: 10.1038/sj.bjc.6600467.
2
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.亚叶酸钙与氟尿嘧啶联合或不联合奥沙利铂作为晚期结直肠癌的一线治疗方案。
J Clin Oncol. 2000 Aug;18(16):2938-47. doi: 10.1200/JCO.2000.18.16.2938.
3
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer.FOXFIRE、SIRFLOX和FOXFIRE-全球转移性结直肠癌患者一线化疗+/-选择性体内放射治疗随机III期试验联合分析方案
JMIR Res Protoc. 2017 Mar 28;6(3):e43. doi: 10.2196/resprot.7201.
4
Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.奥沙利铂/卡培他滨与奥沙利铂/持续输注 5-FU 治疗晚期结直肠癌：MRC COIN 试验。
Br J Cancer. 2012 Sep 25;107(7):1037-43. doi: 10.1038/bjc.2012.384. Epub 2012 Aug 30.
5
Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis.随机森林分析结直肠癌 FOLFOX 治疗的潜在反应者。
Br J Cancer. 2012 Jan 3;106(1):126-32. doi: 10.1038/bjc.2011.505. Epub 2011 Nov 17.
6
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.奥沙利铂/氟尿嘧啶/亚叶酸钙（FOLFOX4和改良FOLFOX6）用于难治性或晚期结直肠癌患者：日本获批后人群经验
Int J Clin Oncol. 2007 Jun;12(3):218-23. doi: 10.1007/s10147-007-0658-x. Epub 2007 Jun 27.
7
cDNA array analysis for prediction of hepatic metastasis of colorectal carcinoma.用于预测结直肠癌肝转移的cDNA阵列分析
Surg Today. 2006;36(7):608-14. doi: 10.1007/s00595-006-3210-0.
8
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
Invest New Drugs. 2006 Mar;24(2):117-23. doi: 10.1007/s10637-006-2032-7.
伊立替康联合氟尿嘧啶与单纯氟尿嘧啶作为转移性结直肠癌一线治疗的比较：一项多中心随机试验。
Lancet. 2000 Mar 25;355(9209):1041-7. doi: 10.1016/s0140-6736(00)02034-1.
4
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.实体瘤治疗反应评估新指南。欧洲癌症研究与治疗组织、美国国立癌症研究所、加拿大国立癌症研究所。
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205.
5
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.比较每月低剂量亚叶酸钙和氟尿嘧啶推注与每两个月高剂量亚叶酸钙和氟尿嘧啶推注加持续输注用于晚期结直肠癌的随机试验：一项法国多中心研究。
J Clin Oncol. 1997 Feb;15(2):808-15. doi: 10.1200/JCO.1997.15.2.808.
6
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.晚期结直肠癌的治疗费用：治疗方案的回顾性比较
Eur J Cancer. 1996;32A Suppl 5:S13-7. doi: 10.1016/s0959-8049(96)00334-6.
7
Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial.极低剂量的华法林可预防中心静脉导管血栓形成。一项随机前瞻性试验。
Ann Intern Med. 1990 Mar 15;112(6):423-8. doi: 10.7326/0003-4819-76-3-112-6-423.